H
Hirofumi Michimae
Researcher at Kitasato University
Publications - 45
Citations - 1008
Hirofumi Michimae is an academic researcher from Kitasato University. The author has contributed to research in topics: Estimator & Chemotherapy. The author has an hindex of 14, co-authored 36 publications receiving 760 citations.
Papers
More filters
Journal ArticleDOI
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata,Makoto Yasuda,Seiji Isonishi,Fumiaki Takahashi,Hirofumi Michimae,Eizo Kimura,Daisuke Aoki,Toshiko Jobo,Shoji Kodama,Fumitoshi Terauchi,Toru Sugiyama,Kazunori Ochiai +11 more
TL;DR: Dose-dense treatment offers better survival than conventional treatment and is a potential new standard of care for first-line chemotherapy for patients with advanced epithelial ovarian cancer.
Journal ArticleDOI
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial
Kaoru Kubota,Hiroshi Sakai,Nobuyuki Katakami,Makoto Nishio,Akira Inoue,Hiroaki Okamoto,Hiroaki Isobe,Hideo Kunitoh,Yuichi Takiguchi,Kazuhiko Kobayashi,Yoichi Nakamura,Hironobu Ohmatsu,Shunichi Sugawara,Koichi Minato,Masaaki Fukuda,Akira Yokoyama,Masahiro Takeuchi,Hirofumi Michimae,Akihiko Gemma,S. Kudoh +19 more
TL;DR: S-1 plus cisplatin is an option for the first-line treatment of patients with advanced NSCLC and noninferior to docetaxel plus cis Platin with favorable QoL data.
Journal ArticleDOI
Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Shoji Nagao,Shin Nishio,Hirofumi Michimae,Hiroshi Tanabe,Satoshi Okada,Takeo Otsuki,Maki Tanioka,Keiichi Fujiwara,Mitsuaki Suzuki,Junzo Kigawa +9 more
TL;DR: Platinum-free interval is a predictor of response and survival after second-line platinum-based chemotherapy in patients with recurrent endometrial cancer.
Journal ArticleDOI
Personalized dynamic prediction of death according to tumour progression and high-dimensional genetic factors: Meta-analysis with a joint model.
TL;DR: This work extends the existing joint frailty-copula model to a model allowing for high-dimensional genetic factors and proposes a dynamic prediction formula to predict death given tumour progression events possibly occurring after treatment or surgery.
Journal ArticleDOI
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial
Hiroyuki Nomura,Daisuke Aoki,Hirofumi Michimae,Mika Mizuno,Hidekatsu Nakai,Masahide Arai,M. Sasagawa,Kimio Ushijima,Toru Sugiyama,Motoaki Saito,Hideki Tokunaga,Maki Matoda,Toru Nakanishi,Yoh Watanabe,Fumiaki Takahashi,Toshiaki Saito,Nobuo Yaegashi +16 more
TL;DR: Because each regimen showed adequate tolerability but different toxic effects, taxane plus platinum regimens may be a reasonable alternative to treatment with doxorubicin plus cisplatin as postoperative adjuvant chemotherapy in endometrial cancer.